SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349: 215-224.
  • 2
    Andriole GL, Bostwick DG, Brawley OW, et al; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362: 1192-1202.
  • 3
    Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007; 99: 1375-1383.
  • 4
    Lebdai S, Bigot P, Azzouzi AR. High-grade prostate cancer and finasteride. BJU Int. 2010; 105: 456-459.
  • 5
    Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011; 365: 97-99.
  • 6
    Moyer VA; on behalf of the U.S. Preventive Services Task Force. Screening for prostate cancer: United States Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157: 120-134.
  • 7
    Grover S, Lowensteyn I, Hajek D, Trachtenberg J, Coupal L, Marchand S. Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial? J Urol. 2006; 175( 3 pt 1): 934-938; discussion 938.
  • 8
    Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol. 2005; 23: 1911-1920.
  • 9
    Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med. 2005; 118: 850-857.
  • 10
    Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol. 2010; 37: 202-215.
  • 11
    Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CAJr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila). 2008; 1: 174-181.
  • 12
    Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila). 2008; 1: 182-186.
  • 13
    Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007; 99: 1366-1374.
  • 14
    Prorok PC, Andriole GL, Bresalier RS, et al; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000; 21( suppl 6): 273S-309S.
  • 15
    Andriole GL, Crawford ED, Grubb RL3rd, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360: 1310-1319.
  • 16
    Andriole GL, Crawford ED, Grubb R, et al. Screening for prostate cancer, 13-year update of the results of the prostate component of the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. J Natl Cancer Inst. 2012; 104: 125-132.
  • 17
    Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009; 101: 878-887.
  • 18
    Serfling R, Shulman M, Thompson GI, et al. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. J Urol. 2007; 177: 2352-2356.